window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-5QXBT1ZYW2'); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-5GXNWGJ9'); function BannerImpression(a) { if (jQuery( window ).width() < '800'){ gtag('event', 'Impression', { 'event_category': a, 'event_label': 'Mobile'}); } else { gtag('event', 'Impression', { 'event_category': a, 'event_label': 'Desktop'}); } } function BannerClickW(a) { if (jQuery( window ).width() < '800'){ gtag('event', 'BannerClick', { 'event_category': a, 'event_label': 'Mobile'}); } else { gtag('event', 'BannerClick', { 'event_category': a, 'event_label': 'Desktop'}); } }
Insight
Roberto Ferrara
Roberto Ferrara/X

Roberto Ferrara: Time to tailor chemo-IO in early stage NSCLC

Roberto Ferrara, Medical Oncologist,Researcher in Thoracic Oncology and Molecular Immunology at Vita-Salute San Raffaele University, posted on LinkedIn:

“Time to tailor chemo-IO in early stage NSCLC. Reconstructed individual patient data analysis shows NEOAD= PERIOP in pCR, MPR and no-MPR. PERIOP performs well in pure-MPR (1-10% RVT). While pCR or no-MPR may deserve future descalation or escalation treatment strategies, respectively.”

“Neoadjuvant versus perioperative chemo-immunotherapy according to pathological response in resectable NSCLC: a reconstructed individual patient data meta-analysis”

Authors: Antonio Nuccio et al.

Roberto Ferrara: Time to tailor chemo-IO in early stage NSCLC

Alberto Servetto Alessandra Bulotta Antonio Nuccio Benjamin Besse Biagio Ricciuti cancer Daniele Marinelli Fabio Salomone Giulia Veronesi Giuseppe Viscardi Marina Chiara Garassino NSCLC OncoDaily Oncology Roberto Ferrara Valter Torri